• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

(2024) Phenotypic Disease Modeling for Inflammation: Advancing Immune-targeting Therapies

On-demand Webinar


With an advanced understanding of human biology, it is now recognized that various diseases are influenced by the immune system. However, many chronic inflammatory diseases and autoimmune-related disorders still lack effective medication for patients. Developing immune-targeting therapies has been challenging due to insufficient knowledge of the underlying disease mechanisms and complex interactions between different cell types. Despite growing interest and advancements in anti-inflammatory therapies, most of these therapies fail in phase 2 clinical trials due to insufficient efficacy. Moreover, modeling inflammation with precision and accuracy requires multicellular disease models in a human-relevant manner, which capture key inflammatory mechanisms including endothelial activation, immune adhesion and recruitment, innate immunity, and target tissue functionality.

It becomes clear that better pre-clinical models, which accurately represent inflamed tissue of the human body, are needed to support and improve drug discovery of immune-targeting therapies.

Watch this on-demand webinar with Lenie van den Broek (Director Biology Discovery MIMETAS). Gain insights into MIMETAS’ expertise in 3D disease modeling, as well as drug ranking and selection within the field of inflammation. Learn how comprehensive in vitro inflammation models are pivotal in improving drug discovery and establishing more effective treatments for patients. The webinar will explore, among other topics, the immuno-suppressive and stimulatory nature of the macrophages in Inflammatory Bowel Disease (IBD).

In this webinar, you will:

  • Case study to confirm mechanism of action and rank antibodies in vascular inflammation assay
  • The use of complement activated serum for studying inflammation in an immune competent renal model
  • Capturing IBD-relevant mechanisms in donor-derived multicellular gut organoid models
  • The benefits of partnering with MIMETAS to accelerate your research and improve the selection of your immunomodulatory compounds

 

Access the recording here!

 


Speaker



Lenie van den Broek is Director Biology Discovery of the Model Development department at MIMETAS. She received her BSc and MSc in Life Science Technology from Leiden University and Technical University Delft. At VUmc, she conducted her PhD in the Department of Dermatology. In her current role, she supervises a team of senior and junior scientists and technicians. The specific focus of her research activities are the development of organotypic models for drug screening evaluation within the fields of vasculature, IBD and lung diseases.

 

 

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all